All conditions

Lung Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

107
Trials tracked
8
Recruiting now
35
Australian sites
59
Countries
Country

Showing 107 trials

🇦🇺 AU site

Trial: NCT05388669 — Janssen Research & Development, LLC

NCT05388669 · Janssen Research & Development, LLC
Active, Not Recruiting Phase 3 Est. completion 3 January 2024
🇦🇷 AR 🇦🇺 AU 🇧🇷 BR 🇨🇦 CA 🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with advanced or spreading non-small cell lung cancer (a type of lung cancer) that has been confirmed by a lab test, and your cancer has a specific gene change (mutation)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06188702 — Servier Bio-Innovation LLC

NCT06188702 · Servier Bio-Innovation LLC
Active, Not Recruiting Phase 2 Est. completion 1 May 2027
🇦🇺 AU 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT 🇯🇵 JP

**Who might be able to join this trial:** - You are expected to live for at least 3 months or more. - You are generally active and able to care for yourself, with little to no limitation in daily activities (confirm with trial site for exa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04938817 — Merck Sharp & Dohme LLC

NCT04938817 · Merck Sharp & Dohme LLC
Active, Not Recruiting Phase 2 Est. completion 10 December 2029
🇦🇺 AU 🇦🇹 AT 🇨🇦 CA 🇭🇺 HU 🇮🇱 IL

**Who might be able to join this trial:** - You have been confirmed (through a tissue or cell sample test) to have extensive-stage small cell lung cancer (a type of lung cancer that has spread) and need a second round of treatment. - Your...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02453282 — AstraZeneca

NCT02453282 · AstraZeneca
Active, Not Recruiting Phase 3 Est. completion 4 October 2018
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE

"Who might be able to join this trial: - You must be at least 18 years old. - You must have been diagnosed with a specific advanced form of lung cancer called Stage IV non-small cell lung cancer (NSCLC). - Your lung cancer must not have cer...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05858736 — OncoC4, Inc.

NCT05858736 · OncoC4, Inc.
Active, Not Recruiting Phase 1 Est. completion 31 July 2026
🇦🇺 AU

Who might be able to join this trial: - You must be 18 years of age or older at the time of signing the consent form. - People of all genders may apply; however, women who could become pregnant must have a negative pregnancy test before joi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03893955 — AbbVie

NCT03893955 · AbbVie
Active, Not Recruiting Phase 1 Est. completion 1 March 2026
🇦🇺 AU 🇫🇷 FR 🇮🇱 IL 🇪🇸 ES 🇹🇼 TW

**Who might be able to join this trial:** - Your liver, kidneys, and blood counts must be at healthy enough levels, as shown by recent lab tests. - You must be generally well enough to carry out light activity and care for yourself (a doct...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02609776 — Janssen Research & Development, LLC

NCT02609776 · Janssen Research & Development, LLC
Active, Not Recruiting Phase 1 Est. completion 31 December 2026
🇦🇺 AU 🇨🇦 CA 🇨🇳 CN 🇫🇷 FR 🇯🇵 JP

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed with surgery, confirmed by a lab test on a tissue or cell sample. -...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04904536 — The George Institute

NCT04904536 · The George Institute
Active, Not Recruiting Phase 3 Est. completion 30 June 2025
🇦🇺 AU

Who might be able to join this trial: - You are 18 years of age or older - You have had COVID-19 that was confirmed by a PCR test, a rapid antigen test, or diagnosed according to official guidelines at the time you are screened for the tria...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00982111 — Eli Lilly and Company

NCT00982111 · Eli Lilly and Company
Completed Phase 3 Est. completion 14 November 2012
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with a specific type of non-small cell lung cancer (not the squamous type — for example, adenocarcinoma or large cell) confirmed by a lab test - Your cancer is at Stage IV...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03804554 — Bristol-Myers Squibb

NCT03804554 · Bristol-Myers Squibb
Completed Not Applicable Est. completion 12 August 2021
🇦🇺 AU

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with non-small cell lung cancer (a common type of lung cancer) - You were treated with a medication called nivolumab through a specific Austr...

🇦🇺 AU site

Trial: NCT00005062 — Gustave Roussy, Cancer Campus, Grand Paris

NCT00005062 · Gustave Roussy, Cancer Campus, Grand Paris
Completed Phase 3 Est. completion 1 December 2005
🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇱 CL 🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with small cell lung cancer that is "limited stage," confirmed by a tissue sample (biopsy) - Your cancer has shown a complete response (disappeared, at least on chest X-ray) af...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01772797 — Novartis Pharmaceuticals

NCT01772797 · Novartis Pharmaceuticals
Completed Phase 1 Est. completion 1 January 2016
🇦🇺 AU 🇮🇹 IT 🇸🇬 SG 🇪🇸 ES 🇺🇸 US

**Who might be able to join this trial:** - You have advanced or spreading non-small cell lung cancer (NSCLC) that got worse during or after treatment with a specific type of targeted therapy called an ALK inhibitor - Your tumor has been te...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00259064 — AstraZeneca

NCT00259064 · AstraZeneca
Completed Phase 3 Est. completion 1 February 2007
🇦🇺 AU 🇨🇦 CA 🇨🇿 CZ 🇳🇱 NL 🇬🇧 GB

Who might be able to join this trial: - You have been diagnosed with non-small cell lung cancer (NSCLC), confirmed through a tissue or cell sample test - Your lung cancer is either at an advanced local stage (Stage IIIB) or has spread to ot...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02299505 — Novartis Pharmaceuticals

NCT02299505 · Novartis Pharmaceuticals
Completed Phase 1 Est. completion 16 June 2016
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇧🇬 BG

**Who might be able to join this trial:** - You have been diagnosed with advanced non-small cell lung cancer (a specific type called ALK-positive) that is either at a late local stage and cannot be treated with combined therapies, or has sp...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02125461 — AstraZeneca

NCT02125461 · AstraZeneca
Completed Phase 3 Est. completion 13 February 2017
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇨🇱 CL 🇫🇷 FR

Who might be able to join this trial: - You must be at least 18 years old - You must have been diagnosed with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that is at an advanced stage (Stage III) and cannot be re...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00686959 — Eli Lilly and Company

NCT00686959 · Eli Lilly and Company
Completed Phase 3 Est. completion 1 October 2014
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You must have a specific type of lung cancer (non-squamous, non-small cell lung cancer) that is at Stage IIIA or Stage IIIB. - Your cancer must be measurable using scans, such as a CT scan. - You...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01324479 — Novartis Pharmaceuticals

NCT01324479 · Novartis Pharmaceuticals
Completed Phase 1 Est. completion 4 July 2017
🇦🇺 AU 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE Hong Kong

**Who might be able to join this trial:** - There is evidence that a specific protein called c-MET is not working normally in your body (based on lab tests). - You have been diagnosed with a solid tumor (a type of cancer that forms a lump,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00363415 — Eli Lilly and Company

NCT00363415 · Eli Lilly and Company
Completed Phase 3 Est. completion 1 June 2008
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

Who might be able to join this trial: - You have been diagnosed with small cell lung cancer (SCLC) that has spread widely in the body (called "extensive stage") - You are able to take care of yourself day-to-day, even if you are unable to d...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04051827 — Millennium Pharmaceuticals, Inc.

NCT04051827 · Millennium Pharmaceuticals, Inc.
Completed Phase 1 Est. completion 17 December 2020
🇦🇺 AU 🇳🇱 NL 🇸🇬 SG

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer (NSCLC) that is locally advanced, has come back, or has spread to other parts of the body (Stage IV), and surgery or radiation as a main tr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00866970 — CSL Behring

NCT00866970 · CSL Behring
Completed Phase 2 Est. completion 1 August 2009
🇦🇺 AU 🇨🇦 CA 🇬🇪 GE 🇮🇳 IN 🇳🇿 NZ

Who might be able to join this trial: - You have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) that cannot be cured by other treatments, including surgery - You have lost at least 5% of your body weight...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01466660 — Boehringer Ingelheim

NCT01466660 · Boehringer Ingelheim
Completed Phase 2 Est. completion 8 April 2016
🇦🇺 AU 🇨🇦 CA 🇨🇳 CN 🇫🇷 FR 🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with advanced lung cancer (stage IIIB or IV) of a specific type called adenocarcinoma, confirmed by a lab test. - Your tumour has been tested and found to have a specific...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03322566 — Incyte Corporation

NCT03322566 · Incyte Corporation
Completed Phase 2 Est. completion 13 December 2018
🇦🇺 AU 🇨🇦 CA 🇭🇺 HU 🇮🇪 IE 🇮🇱 IL

**Who might be able to join this trial:** - You have been diagnosed with advanced (stage IV) non-small cell lung cancer (NSCLC) confirmed by a lab test, and your cancer does not have certain specific genetic changes (called EGFR mutations,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01999673 — Peregrine Pharmaceuticals

NCT01999673 · Peregrine Pharmaceuticals
Completed Phase 3 Est. completion 1 March 2017
🇦🇺 AU 🇧🇪 BE 🇫🇷 FR 🇩🇪 DE 🇬🇷 GR

Who might be able to join this trial: - You are at least 18 years old (male or female) - You have been diagnosed with a specific type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) at an advanced stage (stage IIIb or...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01587703 — GlaxoSmithKline

NCT01587703 · GlaxoSmithKline
Completed Phase 1 Est. completion 13 April 2018
🇦🇺 AU 🇫🇷 FR 🇳🇱 NL 🇰🇷 KR 🇪🇸 ES

**Who might be able to join this trial:** - You are 16 years of age or older at the time of signing the consent form. - You are able to understand and sign a consent form; if you are under 18, a parent or guardian must also give their cons...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05858164 — Bayer

NCT05858164 · Bayer
Completed Phase 1 Est. completion 26 September 2025
🇦🇺 AU 🇨🇳 CN 🇮🇱 IL 🇰🇷 KR 🇪🇸 ES

**Who might be able to join this trial:** - You must be 18 years of age or older at the time of signing the consent form. - You must be able to understand and sign a consent form agreeing to take part in the trial. - You must have a solid...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07174583 — IDEAYA Biosciences

NCT07174583 · IDEAYA Biosciences
Recruiting Phase 2 Est. completion 1 May 2029
🇦🇺 AU 🇧🇷 BR 🇨🇦 CA 🇯🇵 JP 🇰🇷 KR

**Who might be able to join this trial:** - You are willing to take part, understand what the study involves, and can sign a consent form. - You have been diagnosed with a specific type of cancer confirmed by a lab test — including advance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06712355 — BioNTech SE

NCT06712355 · BioNTech SE
Recruiting Phase 3 Est. completion 1 December 2028
🇦🇺 AU 🇨🇳 CN 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC), confirmed by a lab test on a tissue or cell sample. - You have not had any previous systemic (whole-body) treatment...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07472517 — Boehringer Ingelheim

NCT07472517 · Boehringer Ingelheim
Recruiting Phase 3 Est. completion 9 September 2028
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with small cell lung cancer that has spread widely in the body (called "extensive-stage"), and this has been confirmed through a tissue test (biopsy). - You have not had a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06868277 — AstraZeneca

NCT06868277 · AstraZeneca
Recruiting Phase 3 Est. completion 17 January 2030
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇧🇬 BG

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by a lab test, of any type. - Your lung cancer has spread to other parts of the body (Stage IV) and cannot be cured with...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07005102 — AbbVie

NCT07005102 · AbbVie
Recruiting Phase 3 Est. completion 1 December 2031
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇨🇳 CN 🇮🇱 IL

**Who might be able to join this trial:** - You are generally healthy and active enough to carry out light activities, even if you cannot do heavy physical work (your doctor will assess this using a standard scale). - You are willing to pr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07354074 — Novartis Pharmaceuticals

NCT07354074 · Novartis Pharmaceuticals
Recruiting Phase 2 Est. completion 23 February 2033
🇦🇺 AU 🇨🇦 CA 🇰🇷 KR

**Who might be able to join this trial:** - You must be willing and able to sign a consent form before joining the study (for children, a parent or guardian will do this) - You must be aged 1 year old up to (but not including) 18 years old...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05910827 — Hummingbird Bioscience

NCT05910827 · Hummingbird Bioscience
Recruiting Phase 2 Est. completion 1 December 2027
🇦🇺 AU Moldova 🇸🇬 SG 🇰🇷 KR 🇹🇼 TW

**Who might be able to join this trial:** - You must be able to understand and agree to sign a consent form to participate in the study - You must be 18 years of age or older (or the age of majority in your country if that is higher than 1...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07144280 — Pfizer

NCT07144280 · Pfizer
Recruiting Phase 3 Est. completion 10 March 2028
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇬 BG 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that is either advanced and cannot be surgically removed, or has spread to other parts of the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02014116 — Eli Lilly and Company

NCT02014116 · Eli Lilly and Company
Terminated Phase 1 Est. completion 7 April 2017
🇦🇺 AU 🇫🇷 FR 🇪🇸 ES 🇺🇸 US

Who might be able to join this trial: - You have advanced or metastatic cancer (cancer that has spread or is in a late stage) - Other treatments you have tried have not worked to cure your cancer - Your type of cancer does not have a proven...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04866017 — BeiGene

NCT04866017 · BeiGene
Terminated Phase 3 Est. completion 17 October 2023
🇦🇺 AU 🇨🇳 CN 🇪🇸 ES 🇹🇼 TW 🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older (or meet the legal age of consent in your country) at the time of signing the consent form. - You must have been diagnosed with a specific type of lung cancer (non-sm...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05786625 — Creo Medical Limited

NCT05786625 · Creo Medical Limited
Active, Not Recruiting Not Applicable Est. completion 26 November 2025
🇳🇱 NL 🇬🇧 GB

**Who might be able to join this trial:** - You have agreed to take part by signing a consent form - You are 18 years old or older - You have one or more spots or lumps in your lung that have been confirmed as cancer, or are strongly suspe...

Trial: NCT02597738 — University of Arkansas

NCT02597738 · University of Arkansas
Active, Not Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** This trial has several different groups (called "cohorts"). Please check which group may apply to you: **Group A – Lung or Head and Neck Cancer:** - You have lung cancer, head and neck cancer, or...

Trial: NCT04968548 — Nucleix Ltd.

NCT04968548 · Nucleix Ltd.
Active, Not Recruiting Not Applicable Est. completion 1 December 2025
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You are a current or former smoker with a smoking history of at least 20 "pack-years" (for example, smoking one pack a day for 20 years, or two packs a day for 10 years) - You either have a stron...

Trial: NCT03753685 — Fudan University

NCT03753685 · Fudan University
Active, Not Recruiting Phase 2 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - Your lung cancer (non-small cell type) has been confirmed by a lab test and has a specific gene change called an ALK mutation. - You have brain metastases (cancer that has spread to the brain) con...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05773092 — National Cancer Centre, Singapore

NCT05773092 · National Cancer Centre, Singapore
Active, Not Recruiting Phase 2 Est. completion 24 October 2025
🇸🇬 SG

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer (NSCLC) that has a specific gene change called an EGFR mutation, confirmed by a lab test. - Your cancer has at least one tumor that is larg...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05401786 — The Netherlands Cancer Institute

NCT05401786 · The Netherlands Cancer Institute
Active, Not Recruiting Phase 2 Est. completion 15 November 2024
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with advanced non-small cell lung cancer (NSCLC) that has come back or continued to spread, regardless of the specific type of NSCLC. - You are willing and able to sign a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05653752 — MediLink Therapeutics (Suzhou) Co., Ltd.

NCT05653752 · MediLink Therapeutics (Suzhou) Co., Ltd.
Active, Not Recruiting Phase 1 Est. completion 1 December 2026
🇨🇳 CN 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older. - You are well enough to carry out light activities and take care of yourself (your doctor can confirm this based on a standard health scale scored 0–2). - Your...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT07512674 — Sir Run Run Shaw Hospital

NCT07512674 · Sir Run Run Shaw Hospital
Active, Not Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily and can sign a consent form, attend follow-up visits, and follow the study plan. - You are 18 years of age or older. - Your cancer started in the colon or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03808558 — David E Gerber

NCT03808558 · David E Gerber
Active, Not Recruiting Phase 2 Est. completion 3 April 2025
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer (NSCLC) that has spread or is at an advanced stage, confirmed by a lab test, and your tumor has a specific gene change called a KRAS mutati...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03909334 — Xiuning Le

NCT03909334 · Xiuning Le
Active, Not Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be at least 18 years old at the time you give your consent to participate. - You must sign a consent form agreeing to take part and allowing your health information to be used for the st...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06148636 — David Bushnell

NCT06148636 · David Bushnell
Active, Not Recruiting Early Phase 1 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 80 years old - You have been diagnosed with a slow-growing (grade 1 or grade 2) neuroendocrine tumor, confirmed by a tissue or cell sample - Your cancer cannot be cured by...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06132607 — Erik de Loos

NCT06132607 · Erik de Loos
Completed Not Applicable Est. completion 13 March 2023
🇳🇱 NL

Who might be able to join this trial: - You have suspected or confirmed lung cancer (either suspected or proven by a biopsy) and are scheduled to have a type of keyhole lung surgery to remove a lobe or segment of the lung Who may not be ab...

Trial: NCT00002506 — Hoag Memorial Hospital Presbyterian

NCT00002506 · Hoag Memorial Hospital Presbyterian
Completed Phase 2 Est. completion 1 January 1996
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with squamous cell carcinoma (a type of cancer) confirmed by a tissue test (biopsy) - Your cancer has not responded to standard treatments for local disease, or to systemic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00182806 — Roswell Park Cancer Institute

NCT00182806 · Roswell Park Cancer Institute
Completed Phase 2 Est. completion 1 September 2007
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with non-small cell lung cancer (NSCLC), confirmed by a tissue or cell sample test. - Your cancer is either stage IIIA or IIIB and has gotten worse/progressed, OR it is stage I...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03068507 — Peking Union Medical College Hospital

NCT03068507 · Peking Union Medical College Hospital
Completed Not Applicable Est. completion 1 December 2017
🇨🇳 CN

**Who might be able to join this trial:** - You are an outpatient being seen by the thoracic (chest) surgery department at Peking Union Medical College Hospital - You are between 18 and 70 years old - You are suspected of having lung cancer...

Trial: NCT04878016 — Lee's Pharmaceutical Limited

NCT04878016 · Lee's Pharmaceutical Limited
Completed Phase 3 Est. completion 13 October 2023
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older (any gender) - You have been diagnosed with Small Cell Lung Cancer (SCLC) confirmed by a tissue or cell sample test - Your SCLC is at an advanced (extensive) stag...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02839265 — Montefiore Medical Center

NCT02839265 · Montefiore Medical Center
Completed Phase 2 Est. completion 5 October 2022
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with advanced non-small cell lung cancer (stage 3 or 4), confirmed by a biopsy or tissue sample, that cannot be cured - You are 18 years old or older - You have already re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Completed Not Applicable Est. completion 28 October 2022
🇪🇸 ES

**Who might be able to join this trial:** - You have been diagnosed with a chest (thoracic) tumour that has been confirmed through a tissue or cell sample test - You are under 18 years old (confirm with trial site) - You are reasonably acti...

Trial: NCT04640870 — Hellenic Cooperative Oncology Group

NCT04640870 · Hellenic Cooperative Oncology Group
Completed Not Applicable Est. completion 1 March 2020

Who might be able to join this trial: - You are older than 18 years of age - You have been diagnosed with a type of lung cancer called non-small cell lung cancer - Your cancer has spread to other parts of the body (metastatic disease) - You...

Trial: NCT01606748 — Eli Lilly and Company

NCT01606748 · Eli Lilly and Company
Completed Phase 2 Est. completion 1 June 2013
🇺🇸 US

**Who might be able to join this trial:** - You have an advanced or spreading solid tumor cancer (not colorectal cancer with a KRAS mutation) that has stopped responding to standard treatments, or no standard treatment is available for you...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03535363 — Case Comprehensive Cancer Center

NCT03535363 · Case Comprehensive Cancer Center
Completed Phase 1 Est. completion 1 April 2022
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of lung cancer (non-small cell lung cancer) that has a particular genetic change called an EGFR mutation, and it has spread to the brain (new brain me...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02979821 — Korean Association for the Study of Targeted Therapy

NCT02979821 · Korean Association for the Study of Targeted Thera...
Completed Phase 2 Est. completion 1 December 2017
🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed with stage IV lung adenocarcinoma (an advanced form of lung cancer) - Your tumor has a specific genetic change called a HER2 mutation, confirmed by genetic testing — and yo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01015963 — Alliance for Clinical Trials in Oncology

NCT01015963 · Alliance for Clinical Trials in Oncology
Completed Not Applicable Est. completion 1 January 2013

Who might be able to join this trial: - You must have already been registered in a previous study called CALGB 9871 - There must be stored biological samples from you held at the CALGB Pathology Coordinating Office that are sufficient in qu...

Trial: NCT06052449 — Hackensack Meridian Health

NCT06052449 · Hackensack Meridian Health
Completed Not Applicable Est. completion 19 August 2025
🇺🇸 US

Who might be able to join this trial: - You are between 50 and 80 years old - You currently smoke, or you quit smoking within the last 15 years - You have a smoking history of at least 20 pack-years (this means, for example, smoking one pac...

Trial: NCT00454194 — Alliance for Clinical Trials in Oncology

NCT00454194 · Alliance for Clinical Trials in Oncology
Completed Phase 2 Est. completion 1 July 2010
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that is not the "squamous cell" type (though a mixed type called adenosquamous is allowed), c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03613363 — Philips Respironics

NCT03613363 · Philips Respironics
Completed Not Applicable Est. completion 7 September 2021
🇺🇸 US

**Who might be able to join this trial:** - You are currently using a mechanical ventilator (a breathing machine) as part of your medical care, and it has been working well for you - You weigh more than 5 kilograms (about 11 pounds) - You h...

Trial: NCT02013206 — Hoffmann-La Roche

NCT02013206 · Hoffmann-La Roche
Completed Phase 2 Est. completion 1 October 2010
🇫🇷 FR 🇩🇪 DE 🇮🇹 IT 🇳🇱 NL 🇪🇸 ES

Who might be able to join this trial: - You must be 18 years of age or older - You have been diagnosed with advanced non-small cell lung cancer (a specific type of lung cancer) that has been confirmed by a tissue sample, at a late stage (st...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01234987 — Technion, Israel Institute of Technology

NCT01234987 · Technion, Israel Institute of Technology
Completed Not Applicable
🇮🇱 IL

Here is the eligibility information in plain English: Who might be able to join this trial: - Your cancer is contained in one area and has not spread (confirm with trial site) - You have not had surgery, chemotherapy, or radiation treatmen...

Trial: NCT00409136 — Brigham and Women's Hospital

NCT00409136 · Brigham and Women's Hospital
Completed Not Applicable Est. completion 1 August 2008
🇺🇸 US

Who might be able to join this trial: - You must be older than 18 years of age - You must have a combined risk score for blood clots (calculated by medical staff) higher than 4 - You must not currently be receiving any medication or physica...

Trial: NCT04672434 — Symphogen A/S

NCT04672434 · Symphogen A/S
Completed Phase 1 Est. completion 22 November 2024
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed (confirmed by biopsy or lab test) with an advanced or metastatic solid tumor that is one of the following: squamous cell carcinoma of the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06629714 — Anhui Medical University

NCT06629714 · Anhui Medical University
Completed Not Applicable Est. completion 20 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with cancer (specifically esophageal, stomach, gastroesophageal junction, or non-small cell lung cancer) confirmed through medical tests, tissue samples, and scans - You h...

Trial: NCT03366480 — Ability Pharmaceuticals SL

NCT03366480 · Ability Pharmaceuticals SL
Completed Phase 2 Est. completion 1 June 2020
🇪🇸 ES

**Who might be able to join this trial:** - You are 18 years of age or older - You are willing and able to give your written agreement to take part in the trial - You have been diagnosed with advanced, returning, or spread endometrial (wom...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04299542 — Chinese University of Hong Kong

NCT04299542 · Chinese University of Hong Kong
Completed Not Applicable Est. completion 22 November 2021
Hong Kong

**Who might be able to join this trial:** - You have one or more spots or areas of concern in your lung (solid or part-solid) that are 1 centimetre or larger in size **Who may not be able to join:** - You are under 18 years old - You are n...

Trial: NCT00006231 — University of Glasgow

NCT00006231 · University of Glasgow
Completed Phase 3
🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs), confirmed by a tissue sample taken through a procedure such as a chest drain, flui...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02910453 — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

NCT02910453 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Pol...
Completed Not Applicable Est. completion 1 October 2015
🇮🇹 IT

Who might be able to join this trial: - The lung tumor must not be located too close to major airways or blood vessels in the lung, based on a CT scan - You must have a type of lung cancer called Non-Small Cell Lung Cancer, at an early to m...

Trial: NCT03673657 — Sun Yat-sen University

NCT03673657 · Sun Yat-sen University
Completed Phase 2 Est. completion 16 March 2020
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer at an advanced stage (stage 3A, 3B, or 3C) that cannot be removed by surgery - You have received a specific combination of chemotherapy and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00603057 — University of Michigan Rogel Cancer Center

NCT00603057 · University of Michigan Rogel Cancer Center
Completed Not Applicable Est. completion 1 September 2013
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of lung cancer called Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC), confirmed by a tissue sample or by a special scan called a FDG-PET th...

Trial: NCT01817686 — Corporal Michael J. Crescenz VA Medical Center

NCT01817686 · Corporal Michael J. Crescenz VA Medical Center
Completed Not Applicable Est. completion 1 June 2015
🇺🇸 US

**Who might be able to join this trial:** - You are over 18 years old - You have been diagnosed with severe or very severe COPD (a serious lung condition that makes breathing difficult) and/or are currently on or eligible for long-term oxyg...

Trial: NCT00076856 — Merck Sharp & Dohme LLC

NCT00076856 · Merck Sharp & Dohme LLC
Completed Phase 2 Est. completion 31 March 2006

"Who might be able to join this trial: - You must be 18 years of age or older - You must have been diagnosed with a specific type of lung cancer called non-small-cell lung cancer (NSCLC), confirmed through a tissue or cell sample - You must...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05490251 — Virginia Commonwealth University

NCT05490251 · Virginia Commonwealth University
Completed Not Applicable Est. completion 31 August 2025
🇺🇸 US

Who might be able to join this trial: - You identify as African American or white and are male - You are between 18 and 75 years old - You currently smoke at least 5 to 10 cigarettes per day Who may not be able to join: - You have a seriou...

Trial: NCT01465802 — Pfizer

NCT01465802 · Pfizer
Completed Phase 2 Est. completion 18 May 2015
🇰🇷 KR 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with advanced non-small cell lung cancer (NSCLC). - *For Groups 1 and 2:* You have already tried at least one standard chemotherapy treatment for your advanced NSCLC, and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02020252 — University of Chicago

NCT02020252 · University of Chicago
Completed Not Applicable Est. completion 1 December 2018
🇺🇸 US

Who might be able to join this trial: - You are an adult (18 or older) - You speak English - You are a woman or a man - You have recently been diagnosed with lung, gastric (stomach), or pancreatic cancer - You are attending your first oncol...

Trial: NCT00712504 — Pfizer

NCT00712504 · Pfizer
Completed Phase 1 Est. completion 1 November 2007
🇺🇸 US

Who might be able to join this trial: - You have an advanced solid tumor (a cancer that forms a solid mass, rather than a blood cancer) that has spread or cannot be removed. - You are in good or fairly good physical health and able to carry...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02566993 — PharmaMar

NCT02566993 · PharmaMar
Completed Phase 3 Est. completion 24 February 2020
🇦🇷 AR 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇧🇬 BG

Who might be able to join this trial: - You must be willing and able to give written consent to take part voluntarily - You must be 18 years old or older - You must have been diagnosed with small-cell lung cancer (SCLC) — confirmed by a lab...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04630015 — University of California, San Francisco

NCT04630015 · University of California, San Francisco
Completed Not Applicable Est. completion 1 May 2023
🇺🇸 US

Who might be able to join this trial: - You speak English - You were treated for any type of cancer at UCSF, have finished your main treatments (such as chemotherapy, radiation, or surgery), and currently show no signs of active cancer - Yo...

Trial: NCT00264433 — Adherex Technologies, Inc.

NCT00264433 · Adherex Technologies, Inc.
Completed Phase 2
🇨🇦 CA 🇺🇸 US

Who might be able to join this trial: - You must be willing and able to sign a consent form agreeing to take part in the study - You must be 18 years of age or older, male or female, and have a solid tumour that has stopped responding to st...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03293433 — University Hospital, Toulouse

NCT03293433 · University Hospital, Toulouse
Completed Not Applicable Est. completion 1 May 2018
🇫🇷 FR

**Who might be able to join this trial:** - You have a chest X-ray that shows one or two small spots on your lung (between 5mm and 30mm in size) that look like they might be cancer, but have not yet been confirmed by a tissue test - If ther...

Trial: NCT02476526 — VA Greater Los Angeles Healthcare System

NCT02476526 · VA Greater Los Angeles Healthcare System
Completed Phase 4 Est. completion 20 November 2017
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Chronic Kidney Disease (CKD) that has been stable for at least 12 months, with kidney function test results falling within a specific range (eGFR between 16 and 60 ml/min/...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04081779 — Fred Hutchinson Cancer Center

NCT04081779 · Fred Hutchinson Cancer Center
Completed Not Applicable Est. completion 31 December 2025
🇺🇸 US

**Who might be able to join this trial:** - You are a cancer survivor who has finished treatment aimed at curing your cancer within the last 5 years (you may still be taking long-term maintenance medications, such as tamoxifen or aromatase...

Trial: NCT05110118 — Shandong Boan Biotechnology Co., Ltd

NCT05110118 · Shandong Boan Biotechnology Co., Ltd
Completed Phase 1 Est. completion 13 January 2021
🇨🇳 CN

**Who might be able to join this trial:** - You are a healthy male volunteer - You are between 18 and 45 years old - You weigh between 50 kg (about 110 lbs) and 100 kg (about 220 lbs) - Your Body Mass Index (BMI) — a measure of body weight...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT07571759 — The Affiliated Brain Hospital of Nanjing Medical University

NCT07571759 · The Affiliated Brain Hospital of Nanjing Medical U...
Completed Not Applicable Est. completion 7 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You have been diagnosed with a brain tumor confirmed by a brain scan and/or tissue sample, and you are scheduled for surgery to remove it (either...

Trial: NCT00051571 — Seagen Inc.

NCT00051571 · Seagen Inc.
Completed Phase 2
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer (NSCLC) that has spread or come back and cannot be removed by surgery, and you have tried at least one but no more than two previous treatm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04333914 — Centre Leon Berard

NCT04333914 · Centre Leon Berard
Completed Phase 2 Est. completion 6 July 2021
🇫🇷 FR

**Who might be able to join this trial:** - Women aged 18 or older, or men aged 60 or older at the time of joining the trial - You have a confirmed diagnosis of an advanced or spreading blood cancer or solid tumour (any type, anywhere in t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02305173 — Instituto Mexicano del Seguro Social

NCT02305173 · Instituto Mexicano del Seguro Social
Completed Phase 3 Est. completion 1 November 2015
🇲🇽 MX

Who might be able to join this trial: - You have been diagnosed with breast cancer Who may not be able to join: - You have been assessed by an anesthesiologist as having serious health problems that make surgery higher risk (known as ASA C...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05447897 — University of Colorado, Denver

NCT05447897 · University of Colorado, Denver
Completed Not Applicable Est. completion 31 May 2023
🇺🇸 US

Who might be able to join this trial: - You work as part of the implementation team at a Federally Qualified Health Center (FQHC) — a type of community health clinic — or at a partner organization that works with them on lung screening prog...

Trial: NCT02777996 — Cancer Prevention and Research Institute, Italy

NCT02777996 · Cancer Prevention and Research Institute, Italy
Completed Not Applicable Est. completion 1 March 2016
🇮🇹 IT

Who might be able to join this trial: - You live in the local area covered by the study and are registered with one of the participating GPs - You are currently a smoker - You used to smoke but stopped less than 8 years ago Who may not be...

Trial: NCT05069662 — Hospices Civils de Lyon

NCT05069662 · Hospices Civils de Lyon
Completed Not Applicable Est. completion 5 January 2022
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years old or older - You must be an outpatient (not admitted to hospital) who is taking cancer treatment in pill or capsule form and is part of the ONCORAL program, which provides speci...

Trial: NCT02810262 — Hospices Civils de Lyon

NCT02810262 · Hospices Civils de Lyon
Completed Not Applicable Est. completion 1 December 2019
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older - You can be either male or female - You are covered by French National Health Insurance - You have been diagnosed with bone metastases (cancer that has spread to the bon...

Trial: NCT04815447 — University Hospital, Montpellier

NCT04815447 · University Hospital, Montpellier
Completed Not Applicable Est. completion 1 February 2021
🇫🇷 FR

**Who might be able to join this trial:** **For cancer survivors (CCS group):** - You are between 5 and 25 years old - You have finished your full course of cancer treatment and your cancer is considered to be in remission (no relapse or n...

Trial: NCT02039674 — Merck Sharp & Dohme LLC

NCT02039674 · Merck Sharp & Dohme LLC
Completed Phase 2 Est. completion 7 November 2016

**Who might be able to join this trial:** - You have been diagnosed with advanced non-small cell lung cancer (stage 3B or stage 4). - Your cancer came back more than 1 year after finishing treatment for an earlier stage of lung cancer (sta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00003317 — Alliance for Clinical Trials in Oncology

NCT00003317 · Alliance for Clinical Trials in Oncology
Completed Phase 3 Est. completion 1 June 2005
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with stage IIIA non-small cell lung cancer, confirmed by a tissue sample (biopsy) - Your cancer was fully removed through lung surgery (s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01309087 — Allegro Diagnostics, Corp.

NCT01309087 · Allegro Diagnostics, Corp.
Completed Not Applicable Est. completion 1 May 2013
🇨🇦 CA 🇮🇪 IE 🇺🇸 US

Who might be able to join this trial: - You are being checked to see if you might have lung cancer, and your doctor has recommended a bronchoscopy (a procedure to look inside your airways) - You are scheduled to have a bronchoscopy - You ar...

Trial: NCT01737502 — Mayo Clinic

NCT01737502 · Mayo Clinic
Completed Phase 2 Est. completion 24 April 2023
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with lung cancer (specifically squamous cell, a type called RAS-mutated adenocarcinoma, or small cell lung cancer), confirmed by a tissue or cell sample test - You have already...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01579994 — Memorial Sloan Kettering Cancer Center

NCT01579994 · Memorial Sloan Kettering Cancer Center
Completed Phase 1 Est. completion 28 December 2020
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with advanced lung adenocarcinoma (a specific type of lung cancer) that has spread locally or to other parts of the body (stage III or IV), confirmed by testing at MSKCC....

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00250068 — University of New Mexico

NCT00250068 · University of New Mexico
Completed Phase 2 Est. completion 1 December 2007
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older and have lung cancer that can be surgically removed (any stage), or have advanced, returning, or non-removable non-small-cell lung cancer (stage 3b or 4) where sta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01951482 — Sun Yat-sen University

NCT01951482 · Sun Yat-sen University
Completed Phase 3 Est. completion 1 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of lung cancer called non-squamous non-small cell lung cancer (NSCLC), confirmed by a lab test, and your cancer does not have certain genetic features...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00327288 — AmpliMed Corporation

NCT00327288 · AmpliMed Corporation
Completed Phase 1 Est. completion 1 July 2008
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with breast, lung, or prostate cancer that has been previously treated, and the chemotherapy drug docetaxel has been recommended as a treatment option. - You have already recei...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01733589 — Zhejiang Cancer Hospital

NCT01733589 · Zhejiang Cancer Hospital
Completed Phase 2 Est. completion 1 June 2015
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by a tissue or cell sample, and have not yet received treatment for it - Your lung cancer is at an advanced stage (stage I...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00388089 — University of California, Davis

NCT00388089 · University of California, Davis
Completed Phase 1 Est. completion 1 November 2007
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with an advanced solid tumor (a cancer that has spread or cannot be removed), confirmed by a lab test on a tissue or cell sample - Your cancer has continued to grow or spr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02674568 — AbbVie

NCT02674568 · AbbVie
Completed Phase 2 Est. completion 19 October 2018

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with small cell lung cancer (SCLC) that has been confirmed by a tissue test, and your cancer has continued to grow or spread after at least 2...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00452244 — National Cancer Center, Korea

NCT00452244 · National Cancer Center, Korea
Completed Phase 2 Est. completion 1 February 2011
🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer (NSCLC), confirmed by a lab test on a tissue or cell sample - Your cancer is at an advanced stage (Stage IV, or Stage IIIB with fluid aroun...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)